Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Peacock

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, CanadaKarissa M Johnston, Carlo A Marra, Joseph M Connors, et al.
Familial Cancer|June 1, 2006
Determinants of preferences for genetic counselling in Jewish womenCarmel Apicella, Stuart J Peacock, Lesley Andrews, et al.
British Journal of Haematology|April 22, 2016
Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemiaSonya Cressman, Aly Karsan, Donna E Hogge, et al.
BMC Public Health|July 24, 2019
Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugsSarah Costa, Colene Bentley, Dean A Regier, et al.
Cancer|December 2, 2021
Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancerMegan E Tesch, Caroline Speers, Rekha M Diocee, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 11, 2015
Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experimentDean A Regier, Stuart J Peacock, Reka Pataky, et al.
Health and Quality of Life Outcomes|June 16, 2022
The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation studyHelen McTaggart-Cowan, Madeleine T King, Richard Norman, et al.
BMC Health Services Research|November 2, 2013
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)Mehdi Najafzadeh, Karissa M Johnston, Stuart J Peacock, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|July 24, 2013
Exploring colposcopists' attitudes towards use of HPV testing as a primary screening tool for cervical cancer in British ColumbiaDean A Regier, Kim van der Hoek, Gina Ogilvie, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home CareHsien Seow, Dawn M Guthrie, Tara Stevens, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, CanadaKarissa M Johnston, Carlo A Marra, Joseph M Connors, et al.
Familial Cancer|June 1, 2006
Determinants of preferences for genetic counselling in Jewish womenCarmel Apicella, Stuart J Peacock, Lesley Andrews, et al.
British Journal of Haematology|April 22, 2016
Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemiaSonya Cressman, Aly Karsan, Donna E Hogge, et al.
BMC Public Health|July 24, 2019
Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugsSarah Costa, Colene Bentley, Dean A Regier, et al.
Cancer|December 2, 2021
Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancerMegan E Tesch, Caroline Speers, Rekha M Diocee, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 11, 2015
Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experimentDean A Regier, Stuart J Peacock, Reka Pataky, et al.
Health and Quality of Life Outcomes|June 16, 2022
The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation studyHelen McTaggart-Cowan, Madeleine T King, Richard Norman, et al.
BMC Health Services Research|November 2, 2013
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE)Mehdi Najafzadeh, Karissa M Johnston, Stuart J Peacock, et al.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|July 24, 2013
Exploring colposcopists' attitudes towards use of HPV testing as a primary screening tool for cervical cancer in British ColumbiaDean A Regier, Kim van der Hoek, Gina Ogilvie, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home CareHsien Seow, Dawn M Guthrie, Tara Stevens, et al.
Pageof 5